Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses

Journal of Clinical Pathology

Volumn 58, Issue 12, 2005, Pages 1315-1320

  Van Heek, N T ^a   Clayton, S J ^b   Sturm, P D J ^a   Walker, J ^b   Gouma, D J ^c   Noorduyn, L A ^a   Offerhaus, G J A ^a   Fox, J C ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c AstraZeneca ^*

Author keywords

[No Author keywords available]

Indexed keywords

DNA; OLIGONUCLEOTIDE;

ADULT; AGED; ALLELE; AMPLIFICATION REFRACTORY MUTATION SYSTEM; ARTICLE; CONTROLLED STUDY; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DNA HYBRIDIZATION; DNA MICROARRAY; EARLY DIAGNOSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXTRAHEPATIC BILE DUCT OBSTRUCTION; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLESTASIS, EXTRAHEPATIC; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 28644447595     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.022707     Document Type: Article

References (47)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
2. Hirsch-Ginsberg C. Detection of minimal residual disease: relevance for diagnosis and treatment of human malignancies. Annu Rev Med 1998;49:111-22.
3. Leichman CG. Thymidylate synthase as a predictor of response. Oncology (Huntingt) 1998;12:43-7.
4. Findlay MP, Cunningham D, Morgan G, et al. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997;75:903-9.
5. Davidson BR. Progress in determining the nature of bile duct strictures. Gut 1993;34:725-6.
6. Lee JG, Leung JW, Baillie J, et al. Benign, dysplastic, or malignant-making sense of endoscopic bile duct brush cytology: results in 149 consecutive patients. Am J Gastroenterol 1995;90:722-6.
7. Sturm PD, Rauws EA, Hruban RH, et al. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res 1999;5:629-35.
8. Bardales RH, Stanley MW, Simpson DD, et al. Diagnostic value of brush cytology in the diagnosis of duodenal, biliary, and ampullary neoplasms. Am J Clin Pathol 1998;109:540-8.
9. Ponchon T, Gagnon P, Berger F, et al. Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest Endosc 1995;42:565-72.
10. Watanabe M, Asaka M, Tanaka J, et al. Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology 1994;107:1147-53.
11. van Heek NT, Rauws EA, Caspers E, et al. Long-term follow-up of patients with a clinically benign extrahepatic biliary stenosis and K-ras mutation in endobiliary brush cytology. Gastrointest Endosc 2002;55:883-8.
12. Schneider G, Schmid RM. Genetic alterations in pancreatic carcinoma. Mol Cancer 2003;2:15.
13. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
14. Sohn TA, Yeo G, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.
15. Sturm PD, Hruban RH, Ramsoekh TB, et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol 1998;186:247-53.
16. Wilentz RE, Chung CH, Sturm PD, et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer 1998;82:96-103.
17. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-54.
18. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
19. Fox JC, England J, White P, et al. The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system. Br J Cancer 1998;77:1267-74.
20. Clayton SJ, Scott FM, Walker J, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 2000;46:1929-38.
21. Klein AP, Beaty TH, Bailey-Wilson JE, et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002;23:133-49.
22. Chung CH, Wilentz RE, Polak MM, et al. Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol 1996;49:460-4.
23. Hruban RH, Sturm PD, Slebos RJ, et al. Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients. Am J Pathol 1997;151:943-9.
24. Ferrari AP Jr, Lichtenstein DR, Slivka A, et al. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc 1994;40:140-5.
25. Rabinovitz M, Zajko AB, Hassanein T, et al. Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures. Hepatology 1990;12:747-52.
26. Motojima K, Tsunoda T, Kanematsu T, et al. Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Ann Surg 1991;214:657-62.
27. Rijken AM, van Gulik TM, Polak MM, et al. Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. J Surg Oncol 1998;68:187-92.
28. Suto T, Habano W, Sugai T, et al. Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol 2000;73:158-63.
29. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin N Am 2002;11:995-1009.
30. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999;31:305-9.
31. van Heek T, Rader AE, Offerhaus GJ, et al. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002;117:755-65.
32. Tada M, Komatsu Y, Kawabe T, et al. Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Castroenterol 2002;97:2263-70.
33. Kondo H, Sugano K, Fukayama N, et al. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 1997;79:900-5.
34. Furuya N, Kawa S, Akamatsu T, et al. Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice. Gastroenterology 1997;113:593-8.
35. Song MM, Nio Y, Sato Y, et al. Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas. Int J Pancreatol 1996;20:85-93.
36. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72.
37. Hruban RH, Wilentz RE, Goggins M, et al. Pathology of incipient pancreatic cancer. Ann Oncol 1999;10:9-11.
38. Klein WM, Hruban RH, Klein-Szanto AJ, et al. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 2002;15:441-7.
39. Berthelemy P, Bouisson M, Escourrou J, et al. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995;123:188-91.
40. Brat DJ, Lillemoe KD, Yeo CJ, et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol 1998;22:163-9.
41. Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7:738-44.
42. Hruban RH, Petersen GM, Goggins M, et al. Familial pancreatic cancer. Ann Oncol 1999;10(suppl 4):69-73.
43. Lynch HT, Deters CA, Lynch JF, et al. Challenging pancreatic cancer-prone pedigrees: a nosologic dilemma. Am J Gastroenterol 2002;97:3062-70.
44. Lynch HT, Brand RE, Lynch JF, et al. Hereditary factors in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:12-31.
45. Brentnall TA. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am 2000;84:707-18.
46. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131:247-55.
47. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002;160:1239-49.